Exchange Bulletin

InMed Pharmaceuticals Inc (IN) To Trade On Toronto Stock Exchange


March 22, 2018

Issuer: InMed Pharmaceuticals Inc

Issuer: InMed Pharmaceuticals Inc. (“InMed”)
Security: Common Shares (the “Shares”)
Symbol(s): IN
Number of securities issued and outstanding: 152,265,141 Shares
Number of securities reserved for issuance: 46,445,173 Shares
Listing category: Industrial, Non-Exempt Issuer
Trading currency: CDN$
Listing and posted for trading date: March 26, 2018 (at the opening)
Other market(s): The Shares have been listed on the Canadian Securities Exchange (“CSE”) since May 21, 2014 and trade under the symbol “IN”. The Shares will be delisted from CSE on March 23, 2018 (at the close).
Temporary market maker: RBC Capital Markets
Security ownership registration: Certificated issue
Investor relations: Eric A. Adams
CEO and President
(604) 669-7207 ext. 212
Email: eadams@inmedpharma.com
-and-
Jeff Charpentier
Chief Financial Officer
(604) 669-7207 ext. 213
Email: jcharpentier@inmedpharma.com
Incorporation: Business Corporations Act (British Columbia)
Fiscal year end: June 30
Nature of business: InMed is engaged in researching, developing, manufacturing and commercializing cannabinoid-based biopharmaceutical products to treat diseases with high unmet medical needs.
Transfer agent and registrar: Computershare Investor Services Inc. at its principal offices in Vancouver
Dividends: None anticipated in the foreseeable future.
Sponsorship: Canaccord Genuity Corp.
TSX contact: Julie K. Shin,
Director, Listed Issuer Services,
Toronto Stock Exchange.

v x